Clinical Evaluation of the Results of Treatment of Severe Coronavirus Disease (COVID-19) Caused by SARS-COV-2 in Patients with Pneumonia and Pneumo-Pleurofibrosis Using Modern Pharmacotherapy to Protect Public Health
Open Access
- 1 January 2026
- journal article
- Published by Shapovalov Scientific Publishing OU (Publications) in SSP Modern Pharmacy and Medicine
- Vol. 6 (1) , 16-38
Abstract
The COVID-19 pandemic prompted the development of innovative approaches to the treatment of severe forms of pneumonia with pneumo-pleurofibrosis. An IV regimen based on intravenous administration of ethyl alcohol solutions of different concentrations with glucose in patients with COVID-19 (intervention group and control groups of comparable number) was proposed and clinically evaluated. The use of 10% Ethanol has been introduced: 150 ml intravenously drip 2 times a day for 7 days. In both groups, hyperthermia, tachypnea, dry cough, pleural pain, diffuse cyanosis, severe general condition, a significant decrease in oxygen saturation, leukocytosis and lymphopenia were found at the beginning of treatment. In the intervention group, the normalization of indicators occurred much faster: body temperature returned to normal on the fifth to seventh day versus the twelfth-fourteenth in the control; respiratory rate – on the fourth to fifth day versus the sixteenth to eighteenth; saturation reached normal on the sixth to eighth day against the twelfth-fifteenth; leukocytes returned to normal on the tenth to eleventh day against the sixteenth to eighteenth; Lymphocytes stabilized on the sixth to eighth day versus the twentieth to twenty-second. On the seventh day, a satisfactory condition was observed in most patients in the intervention group without deaths, in the control - much later and in smaller numbers. The technique of using intravenous ethanol is based on the classical principles of detoxification therapy: elimination of the toxic factor with subsequent elimination of the consequences of intoxication, which provides an etiotropic-pathogenetic effect in acute vasculitis and pneumo-pleurofibrosis. The proposed scheme reduces the duration of treatment, reduces costs, and requires further clinical, pharmacological and pharmacoeconomic studies.Keywords
This publication has 58 references indexed in Scilit:
- Clinical management of COVID-19 in hospitals and the community: A snapshot from a medical insurance database in South AfricaInternational Journal of Infectious Diseases, 2022
- COVID-19 Vasculitis and vasculopathy-Distinct immunopathology emerging from the close juxtaposition of Type II Pneumocytes and Pulmonary Endothelial CellsSeminars in Immunopathology, 2022
- A narrative review of the use of alcohol during the Covid-19 pandemic; effects and implicationsJournal of Addictive Diseases, 2022
- COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talkingVirus Research, 2020
- Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health scienceThe Lancet Psychiatry, 2020
- A SARS-CoV-2 protein interaction map reveals targets for drug repurposingNature, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Origin and evolution of pathogenic coronavirusesNature Reviews Microbiology, 2018
- Fomepizole for the Treatment of Methanol PoisoningNew England Journal of Medicine, 2001
- American Academy of Clinical Toxicology Practice Guidelines on the Treatment of Ethylene Glycol PoisoningJournal of Toxicology: Clinical Toxicology, 1999